Yüklüyor......
Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study
This is a prospective, open-label, proof-of-concept study of tofacitinib, a Janus kinase inhibitor, as a steroid sparing therapy in corticosteroid-dependent pulmonary sarcoidosis. 5 patients with corticosteroid-dependent pulmonary sarcoidosis were treated with tofacitinib 5 mg twice daily. The prima...
Kaydedildi:
| Yayımlandı: | Lung |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8092019/ https://ncbi.nlm.nih.gov/pubmed/33825964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00408-021-00436-8 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|